Status:
COMPLETED
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
Lead Sponsor:
Adrian Vella
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
20-65 years
Phase:
EARLY_PHASE1
Brief Summary
The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increase...
Eligibility Criteria
Inclusion
- Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of \> 110 mg/dL
- Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).
Exclusion
- Subjects taking thiazolidinediones
- Subjects with active systemic illness
- Subjects with active microvascular or macrovascular complications of their diabetes
- For female subject: positive pregnancy test at the time of enrollment in study
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01843855
Start Date
June 1 2011
End Date
September 1 2013
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905-0001